CN110353883A - 用于治疗褥疮的复合敷料层及带有复合敷料层的褥疮贴 - Google Patents
用于治疗褥疮的复合敷料层及带有复合敷料层的褥疮贴 Download PDFInfo
- Publication number
- CN110353883A CN110353883A CN201910619442.7A CN201910619442A CN110353883A CN 110353883 A CN110353883 A CN 110353883A CN 201910619442 A CN201910619442 A CN 201910619442A CN 110353883 A CN110353883 A CN 110353883A
- Authority
- CN
- China
- Prior art keywords
- layer
- bedsore
- combine dressing
- dressing layer
- patch
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000004210 Pressure Ulcer Diseases 0.000 title claims abstract description 46
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 43
- 206010052428 Wound Diseases 0.000 claims abstract description 41
- 235000012907 honey Nutrition 0.000 claims abstract description 26
- 229920000615 alginic acid Polymers 0.000 claims description 12
- 235000010443 alginic acid Nutrition 0.000 claims description 12
- 235000016887 Leptospermum scoparium Nutrition 0.000 claims description 5
- 240000003553 Leptospermum scoparium Species 0.000 claims description 5
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims description 5
- 239000003921 oil Substances 0.000 claims description 5
- 229910052710 silicon Inorganic materials 0.000 claims description 5
- 239000010703 silicon Substances 0.000 claims description 5
- 230000003447 ipsilateral effect Effects 0.000 claims description 3
- 241000195493 Cryptophyta Species 0.000 claims 1
- 230000035876 healing Effects 0.000 abstract description 8
- 239000003102 growth factor Substances 0.000 abstract description 7
- 230000008520 organization Effects 0.000 abstract description 5
- 230000014759 maintenance of location Effects 0.000 abstract description 3
- 238000003672 processing method Methods 0.000 abstract description 3
- 238000005516 engineering process Methods 0.000 abstract description 2
- 210000001772 blood platelet Anatomy 0.000 description 29
- 239000000499 gel Substances 0.000 description 23
- 239000008280 blood Substances 0.000 description 7
- 230000029663 wound healing Effects 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 6
- 210000004623 platelet-rich plasma Anatomy 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 206010011985 Decubitus ulcer Diseases 0.000 description 5
- 230000006378 damage Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 3
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 2
- 101800003838 Epidermal growth factor Proteins 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- AIJULSRZWUXGPQ-UHFFFAOYSA-N Methylglyoxal Chemical compound CC(=O)C=O AIJULSRZWUXGPQ-UHFFFAOYSA-N 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000001804 debridement Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229940116977 epidermal growth factor Drugs 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000005755 Intercellular Signaling Peptides and Proteins Human genes 0.000 description 1
- 108010070716 Intercellular Signaling Peptides and Proteins Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000010478 bone regeneration Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000008472 epithelial growth Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000005424 photoluminescence Methods 0.000 description 1
- 230000010118 platelet activation Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive bandages or dressings
- A61F13/0203—Adhesive bandages or dressings with fluid retention members
- A61F13/0213—Adhesive bandages or dressings with fluid retention members the fluid retention member being a layer of hydrocolloid, gel forming material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive bandages or dressings
- A61F13/0246—Adhesive bandages or dressings characterised by the skin-adhering layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive bandages or dressings
- A61F13/0276—Apparatus or processes for manufacturing adhesive dressings or bandages
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Manufacturing & Machinery (AREA)
- Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Materials For Medical Uses (AREA)
Abstract
本发明涉及医疗技术领域,公开了用于治疗褥疮的复合敷料层及带有复合敷料层的褥疮贴,其中的复合敷料层包括可敷设于患者创面的富血小板凝胶层和用于覆盖富血小板凝胶层的蜂蜜层。本发明利用富血小板凝胶层敷于患者的创面,并采用蜂蜜敷料加以覆盖,保湿性好,同时也克服了常规伤口处理方法中生长因子缺乏、组织愈合骨架少、爬皮不易和容易感染等缺点。
Description
技术领域
本发明涉及医疗技术领域,具体涉及用于治疗褥疮的复合敷料层及带有复合敷料层的褥疮贴。
背景技术
褥疮又称压疮、压力性溃疡,是由于局部组织长期受压,发生持续缺血、缺氧、营养不良而致组织溃烂坏死。褥疮的发病率高,尤其3-4期压力性损伤的治疗是全球性难题,好发于脑卒中、大型手术后、糖尿病等长期卧床患者,容易合并或诱发全身感染,导致住院天数延长、治疗困难及预后不良的恶性循环。
现阶段对于褥疮的治疗主要包括:1、单用血小板衍生因子(PDGF);2、电刺激;3、负压吸引疗法;4、手术治疗等。以上治疗方案主要存在以下缺陷:1)治疗费用昂贵;2)治疗手段单一,疗效不佳;3)易合并感染。
湿性医疗技术是近几年主流的伤口治疗方法,在充分清创的基础上让创面保持湿润及密闭,辅以全身营养支持及原发疾病治疗,为伤口的愈合提供有利的湿性环境。但临床实践中,经过上述处理仍有部分伤口经久不愈,创面易感染等问题;即使在运用商品化生长因子的情况下(如成纤维细胞生长因子等),效果仍不佳。
发明内容
基于以上问题,本发明提供用于治疗褥疮的复合敷料层及带有复合敷料层的褥疮贴,利用富血小板凝胶层敷于患者的创面,并采用蜂蜜敷料加以覆盖,保湿性好,同时也克服了常规伤口处理方法中生长因子缺乏、组织愈合骨架少、爬皮不易和容易感染等缺点。
为解决以上技术问题,本发明提供了用于治疗褥疮的复合敷料层,包括可敷设于患者创面的富血小板凝胶层和用于覆盖富血小板凝胶层的蜂蜜层。
进一步地,富血小板凝胶层为自体富血小板凝胶。
进一步地,蜂蜜层为麦卢卡蜂蜜。
为解决以上技术问题,本发明还提供了带有复合敷料层的褥疮贴,包括贴布,贴布中部位置设置有复合敷料层,复合敷料层的蜂蜜层介于富血小板凝胶层和贴布之间。
进一步地,褥疮贴设置有藻酸盐,藻酸盐与复合敷料层位于贴布的同侧,且藻酸盐设置于复合敷料层的边缘。
进一步地,褥疮贴还设置有用于覆盖藻酸盐和复合敷料层的硅油离型纸层。
与现有技术相比,本发明的有益效果是:本发明提供的复合敷料层以及带有复合敷料层的褥疮贴均利用富血小板凝胶层敷于患者的创面,并采用蜂蜜敷料加以覆盖,保湿性好,同时也克服了常规伤口处理方法中生长因子缺乏、组织愈合骨架少、爬皮不易和容易感染等缺点。
附图说明
图1为实施例1中用于治疗褥疮的复合敷料层的结构示意图;
图2为实施例2中的PUSH评分量表;
图3为实施例3中带有复合敷料层的褥疮贴的结构示意图;
其中,1、富血小板凝胶层;2、蜂蜜层;3、贴布;4、硅油离型纸层。
具体实施方式
为使本发明的目的、技术方案和优点更加清楚明白,下面结合实施例和附图,对本发明作进一步的详细说明,本发明的示意性实施方式及其说明仅用于解释本发明,并不作为对本发明的限定。
实施例1:
参见图1,用于治疗褥疮的复合敷料层,包括可敷设于患者创面的富血小板凝胶层1和用于覆盖富血小板凝胶层1的蜂蜜层2。
在本实施例中,富血小板凝胶敷于褥疮创面,富血小板凝胶是从静脉血中提取的富血小板血浆经凝血酶激活后形成的胶状物,因富血小板凝胶的成分主要包括血小板、白细胞、纤维蛋白原和多种生长因子,其中的生长因子主要有血小板源性生长因子(plalelet-derived growth factor)、血管内皮生长因子(vascular endothelial growth factor)、表皮生长因子(epidermal growth factor)、转移生长因子-β(transforming growthfactor-β)和胰岛素样生长因子(insulin-like growth factor),血小板激活后上述生长因子直接作用于创口表面,与受体结合,促进软组织的再生与修复;另一方面,富血小板凝胶中的白细胞具有抗感染和免疫调节的作用,破裂的血小板覆盖于创口表面,可以杀灭细菌及其他微生物,减轻疼痛,减少出血和分泌物,此外白细胞也可以起到激活生长因子的作用;富血小板凝胶中高浓度的纤维蛋白原提供了组织愈合的骨架,更利于组织的修复、再生。
蜂蜜敷料覆盖在富血小板凝胶上,蜂蜜的pH为3.2-4.5,酸性环境利于血红蛋白释放结合氧,抑制伤口部位基质酶活性,防止新生基质被分解;蜂蜜含有生物活性物质,刺激局部细胞分泌细胞因子,从而减轻炎症反应,促进伤口愈合;高渗糖环境促进伤口淋巴液渗出,有利于伤口愈合,同时促进细菌的溶解;蜂蜜在杀菌同时,不降低细菌的敏感性,亦不产生细菌的耐药性;蜂蜜中含有过氧化氢、甲基乙二醛等天然杀菌物质;同时蜂蜜敷料保湿性好,可对伤口提供营养物质,促进肉芽和上皮生长。
富血小板凝胶层1为自体富血小板凝胶,自体富血小板凝胶制作简单,抽取患者自己的血液,价格便宜,一方面避免了疾病传播的危险和免疫排斥反应,另一方面也减轻患者的经济负担,节省医疗资源。
蜂蜜层2为麦卢卡蜂蜜,麦卢卡蜂蜜所含有的水溶性生物活性因子,不仅能杀灭浮游生长的微生物,亦能渗透入慢性伤口部位的微生物膜中,起到破坏微生物膜的作用;麦卢卡蜂蜜所含有的杀菌物质不易被人体酶类分解,对褥疮的治疗效果更佳。
实施例2:
本实施例选择3-4期的压力性损伤患者10例(符合纳入标准并签署知情同意书,完成输血前检查),通过创面愈合率和压疮愈合量表评分(PUSH)来评估治疗效果。在治疗前评估伤口情况并记录原始创面面积,应用富血小板凝胶联合麦卢卡蜂蜜敷料规律治疗,总疗程为4-8周,以4周为一个疗程,治疗满一个疗程后再次评估伤口情况、记录创面面积、计算创面愈合率。
具体操作流程为:
1)标本采集、预处理:采取患者自身外周静脉血30ml置于50ml离心管(内含1ml的枸橼酸钠)中,轻轻摇晃离心管3-4次;
2)设置离心机的离心力200g,将步骤1)中的离心管在4℃条件下离心10分钟,全血分3层,上层富含大量血小板及少量白细胞,中间白膜层含有高浓度的白细胞,最底层则为红细胞层;
3)将最上层和中间白膜层移置另一离心管中(尽量避免吸取红细胞),在离心机的离心力2500g条件下离心15分钟,离心管底部会形成微量红细胞-血小板微软颗粒,弃去上层2/3血浆,将剩余1/3血浆(约5ml)轻轻摇晃,即制成富血小板血浆(PRP);
4)取少许PRP于血小板计数仪下计数,选择血小板数量高于1000x106/ml)的PRP备用;
5)1000U的牛凝血酶使用10%CaCl2溶液1ml溶解(激活剂),与PRP按约1:10的比例混合,样品即成凝胶状态。
6)将创面清创处理后,将制备好的富血小板凝胶均匀敷于创口表面,使用麦卢卡蜂蜜敷料覆盖,即可形成对创面具有治疗作用的复合敷料层。一周观察两次创面情况并做记录,包括创口面积、有无红肿分泌物、肉芽组织生长情况、创口面积、细菌及病理组织变化。
评估标准:
创面愈合率:创面愈合率=(创面面积-原始创面面积)/原始创面面积x100%,用标准透明格测量创面面积,每周做好相关记录病进行愈合率的计算评估。
PUSH:PUSH是1997年由美国压疮顾问咨询委员会(National Pressure UlcerAdvisory Panel)提出,此量表主要从创面面积、渗出液量及组织形态三方面来进行评价(如图2所示),适用于2期及以上压力性损伤评价,总分17分,0分表示愈合;若同一患者有多处损伤,则应分开评分。
实施例3:
带有复合敷料层的褥疮贴,包括贴布3,贴布3中部位置设置有复合敷料层,复合敷料层的蜂蜜层2介于富血小板凝胶层1和贴布3之间。
在本实施例中,褥疮贴可直接贴于患者的创面上,使复合敷料的富血小板凝胶层1直接与创面接触,可适用于褥疮的治疗。
褥疮贴设置有藻酸盐,藻酸盐与复合敷料层位于贴布的同侧,且藻酸盐设置于复合敷料层的边缘。藻酸盐可以粘附在褥疮周边正常的皮肤上,便于吸收创面的渗液。
褥疮贴还设置有用于覆盖藻酸盐和复合敷料层的硅油离型纸层4,在将褥疮贴敷设至患者创面前可以对复合敷料层起到保护的作用,防止被污染;需要用褥疮贴对患者额褥疮进行覆盖时,只需揭开硅油离型纸层4即可将带有复合敷料层的褥疮贴贴设于患者创面,操作简单,干净卫生。
如上即为本发明的实施例。上述实施例以及实施例中的具体参数仅是为了清楚表述发明验证过程,并非用以限制本发明的专利保护范围,本发明的专利保护范围仍然以其权利要求书为准,凡是运用本发明的说明书及附图内容所作的等同结构变化,同理均应包含在本发明的保护范围内。
Claims (6)
1.用于治疗褥疮的复合敷料层,其特征在于:包括可敷设于患者创面的富血小板凝胶层(1)和用于覆盖富血小板凝胶层(1)的蜂蜜层(2)。
2.根据权利要求1所述的用于治疗褥疮的复合敷料层,其特征在于,所述富血小板凝胶层(1)为自体富血小板凝胶。
3.根据权利要求1或2所述的用于治疗褥疮的复合敷料层,其特征在于:所述蜂蜜层(2)为麦卢卡蜂蜜。
4.带有复合敷料层的褥疮贴,包括贴布(3),其特征在于:所述贴布(3)中部位置设置有如权利要求1-3任意一项所述的复合敷料层,复合敷料层的蜂蜜层(2)介于富血小板凝胶层(1)和贴布(3)之间。
5.根据权利要求4所述的带有复合敷料层的褥疮贴,其特征在于:所述褥疮贴设置有藻酸盐,所述藻酸盐与复合敷料层位于贴布的同侧,且藻酸盐设置于复合敷料层的边缘。
6.根据权利要求5所述的带有复合敷料层的褥疮贴,其特征在于:所述褥疮贴还设置有用于覆盖藻酸盐和复合敷料层的硅油离型纸层(4)。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910619442.7A CN110353883A (zh) | 2019-07-10 | 2019-07-10 | 用于治疗褥疮的复合敷料层及带有复合敷料层的褥疮贴 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910619442.7A CN110353883A (zh) | 2019-07-10 | 2019-07-10 | 用于治疗褥疮的复合敷料层及带有复合敷料层的褥疮贴 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110353883A true CN110353883A (zh) | 2019-10-22 |
Family
ID=68218626
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910619442.7A Pending CN110353883A (zh) | 2019-07-10 | 2019-07-10 | 用于治疗褥疮的复合敷料层及带有复合敷料层的褥疮贴 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110353883A (zh) |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103417581A (zh) * | 2013-08-06 | 2013-12-04 | 天津汉思睿智医药开发有限公司 | 用于伤口治疗的药物组合物 |
CN104159569A (zh) * | 2011-11-23 | 2014-11-19 | 细胞治疗有限公司 | 血小板裂解物凝胶 |
CN204379848U (zh) * | 2014-12-30 | 2015-06-10 | 中国人民解放军第四军医大学 | 一种复合水凝胶创伤敷料 |
CN104758977A (zh) * | 2014-10-11 | 2015-07-08 | 河南亚都实业有限公司 | 一种治疗褥疮的海藻酸盐敷料及其制备方法 |
CN105056285A (zh) * | 2015-09-23 | 2015-11-18 | 广东泰宝医疗科技股份有限公司 | 一种可粘合组织裂隙的生长因子复合敷料及其制备方法 |
CN105688259A (zh) * | 2016-03-14 | 2016-06-22 | 苏州市贝克生物科技有限公司 | 一种治疗褥疮生物敷料的制备方法 |
CN106822183A (zh) * | 2016-12-26 | 2017-06-13 | 上海斯能得医疗科技有限公司 | 一种光敏富血小板血浆凝胶及其制备方法和用途 |
CN107708752A (zh) * | 2015-02-03 | 2018-02-16 | 玛托克控股有限公司 | 抗微生物纤维和组合物 |
CN108136027A (zh) * | 2015-06-19 | 2018-06-08 | 全球健康方案有限责任公司 | 用于活性成分的基于凡士林的递送系统 |
-
2019
- 2019-07-10 CN CN201910619442.7A patent/CN110353883A/zh active Pending
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104159569A (zh) * | 2011-11-23 | 2014-11-19 | 细胞治疗有限公司 | 血小板裂解物凝胶 |
CN103417581A (zh) * | 2013-08-06 | 2013-12-04 | 天津汉思睿智医药开发有限公司 | 用于伤口治疗的药物组合物 |
CN104758977A (zh) * | 2014-10-11 | 2015-07-08 | 河南亚都实业有限公司 | 一种治疗褥疮的海藻酸盐敷料及其制备方法 |
CN204379848U (zh) * | 2014-12-30 | 2015-06-10 | 中国人民解放军第四军医大学 | 一种复合水凝胶创伤敷料 |
CN107708752A (zh) * | 2015-02-03 | 2018-02-16 | 玛托克控股有限公司 | 抗微生物纤维和组合物 |
CN108136027A (zh) * | 2015-06-19 | 2018-06-08 | 全球健康方案有限责任公司 | 用于活性成分的基于凡士林的递送系统 |
CN105056285A (zh) * | 2015-09-23 | 2015-11-18 | 广东泰宝医疗科技股份有限公司 | 一种可粘合组织裂隙的生长因子复合敷料及其制备方法 |
CN105688259A (zh) * | 2016-03-14 | 2016-06-22 | 苏州市贝克生物科技有限公司 | 一种治疗褥疮生物敷料的制备方法 |
CN106822183A (zh) * | 2016-12-26 | 2017-06-13 | 上海斯能得医疗科技有限公司 | 一种光敏富血小板血浆凝胶及其制备方法和用途 |
Non-Patent Citations (1)
Title |
---|
付小兵,王正国: "《创伤基础》", 30 November 2016 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102341130B (zh) | 创伤敷料、用于制造创伤敷料的方法和设备以及其储存和用途 | |
Fonder et al. | Treating the chronic wound: A practical approach to the care of nonhealing wounds and wound care dressings | |
Whelan et al. | Mechanics of wound healing and importance of vacuum assisted closure® in urology | |
US20080215020A1 (en) | Apparatuses and methods for healing wounds | |
US5084281A (en) | Method and solution for treating tissue wounds | |
Dowsett | Exudate management: a patient-centred approach | |
Bello et al. | The role of graftskin (Apligraf) in difficult-to-heal venous leg ulcers | |
US20160346335A1 (en) | Honey-based dressing for the treatment of wounds and burns | |
CN100571773C (zh) | 采用表皮生长因子治疗皮肤伤口的方法和组合物 | |
Sibbald et al. | Wound bed preparation: DIM before DIME: wound care | |
Bowszyc et al. | Comparison of two dressings in the treatment of venous leg ulcers | |
CN110353883A (zh) | 用于治疗褥疮的复合敷料层及带有复合敷料层的褥疮贴 | |
RU2616239C2 (ru) | Способ лечения эрозивно-язвенных поражений кожи | |
CN108969795B (zh) | 一种用于难愈合性创面功能性液体敷料及其制备方法 | |
CN115120708A (zh) | 一种用于治疗糖尿病足的干细胞凝胶 | |
Langemo et al. | Managing fungating wounds | |
Price et al. | Skin repair technology | |
Serena et al. | Multifunctional and patient-focused Mepilex Border Flex: an exploration of its holistic clinical benefits | |
Sibbald et al. | Wound bed preparation and oxygen balance–a new component? | |
Bolton | Moist wound healing from past to present | |
EP0034504A2 (en) | Combinations for the treatment of wounds | |
Bentley | Choosing the right prescribing options in wound debridement | |
CN211095264U (zh) | 一种用于乳腺肿物微创手术的碘伏防水敷料 | |
Yuriiovych et al. | MANAGEMENT STRATEGIES FOR TREATMENT OF CHRONIC WOUNDS | |
Gollamudi et al. | A comparative study on the effectiveness of negative pressure wound therapy versus conventional dressing in patients post skin grafting procedure |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20191022 |
|
RJ01 | Rejection of invention patent application after publication |